Seroprevalence of Cytomegalovirus infection and estimate of congenital Cytomegalovirus infection in Isfahan state, Iran: A population based study

Sayed Nasser Mostafavi1, Behrooz Ataei2, Zari Nokhodian3, Majid Yaran4, Anahita Babak5, Asma Salehi6, Mona Haghighatian7

ABSTRACT

Objective: Cytomegalovirus (CMV) is a well-known virus with major consequences in growing fetus, premature infants, and immune deficient individuals. There are few reports in prevalence of CMV infection in Iran, mainly in pregnant women. We conducted an epidemiological study to investigate the age-stratified seroprevalence and epidemiological characteristics of CMV infection in total inhabitants of Isfahan state, central Iran.

Methodology: In a cross sectional study 595 serum samples which were collected randomly from total population of Isfahan state, Iran were used for IgG anti-CMV antibody titration by a commercial enzyme-linked immunosorbent assay (ELISA) kit. Data were analyzed by Statistical Package for Social Sciences for Windows version 15(SPS5). Chi-sqaur and Fisher exact tests were applied to determine antibody status in different age, gender, education, family member, and residency groups.

Results: The overall prevalence was 98.2 % (586/595). The prevalence in age groups of 6-9, 10-19, 20-29, 30-39, 40-49 and above 49 years were 95.7, 98.6, 97.8, 100, 96.6, and 100 percent respectively. There was no statistical significant association between CMV seroprevalence with age, gender, education, family member, and residency groups (P < 0.05).

Conclusions: This study elucidates a very high prevalence of CMV infection in population which acquired it from early childhood. So it is necessary to initiate measures to reduce the burden of CMV disease in fetuses, premature infants, and immune deficient individuals. To treat hearing loss in inapparent congenitally infected infants, repeated auditory exams up to 5 years old has paramount importance.

KEY WORDS: Epidemiology, Cytomegalovirus, Population based study, Immunoassay.

doi: http://dx.doi.org/10.12669/pjms.291(Suppl).3546

How to cite this:
Mostafavi SN, Ataei B, Nokhodian Z, Yaran M, Babak A, Salehi A, et al. Seroprevalence of Cytomegalovirus infection and estimate of congenital Cytomegalovirus infection in Isfahan state, Iran: A population based study. Pak J Med Sci 2013;29(1)Suppl:418-422.
doi: http://dx.doi.org/10.12669/pjms.291(Suppl).3546

INTRODUCTION

Cytomegalovirus (CMV) is the largest member of the Herpesviridae family with several strains and universal distribution. The humans are the only reservoir and transmission occurs by direct or indirect contact with secretions of the infected people. Primary CMV infection is usually asymptomatic, but the virus remains latent in many organs including kidney, lung, gastrointestinal tract, and genitourinary system. After infection, specific T-cells against CMV antigens produced which protects the host from severe primary, secondary,
or reactivated disease. T-cell immunodefficient individuals mainly fetuses, premature infants, transplant recipients, and HIV patients are at high risk for acquiring serious CMV disease involving any organs certainly liver, pancreas, adrenals, lymph nodes, brain, eyes, heart, skin, genitourinary, and gastrointestinal systems. In contrast, humoral immunity has less significant role in protection against CMV infection and mainly lessens severity of the related symptoms and serves as a marker of previous infection.

Maternal primary or recurrent infection can cause fetal infection. The rate of fetal transmission in primary maternal infection is 40-50 percent while this parameter in recurrent infection approximates one percent. On the other hand symptoms and sequelae of the infection in maternal primary infection are much more than secondary infection.

About 5-15 percent of infants with congenital CMV infection following primary maternal infection shows symptoms of disease at birth mainly as growth retardation, hepatosplenomegaly, thrombocytopenia, pneumonia, microcephaly, cerebral calcification, chorioretinitis, and hearing loss. Another 10-15 percent will show symptoms like hearing loss, visional disorders, and developmental problems later in life. While in fetal infections which occurred following secondary maternal infections few cases were symptomatic at birth and 5-7% of them would developed hearing loss later.

Seroprevalence of CMV infection mostly is directly related to cultural and socioeconomic status of the population. In developing countries most children acquire the infection before reaching the age of three years and almost all persons have been infected before adulthood. In contrast in developed countries and high socioeconomic people many of the population are sero-negative prior to adolescent ages. This pattern of infection influences the rate and severity of the congenital CMV infections. In developed regions the prevalence of maternal primary infection and symptomatic congenital CMV infection is high, while in developing areas recurrent maternal infection and asymptomatic congenital CMV infection is significant.

At this time CMV disease is a cause of morbidity in immunocompromised conditions including transplant recipient and HIV-infected persons. In addition it is a major cause of mental retardation and sensorineural hearing loss in most regions. Despite these, it is not a noticeable disease in most countries. To understand the transmission dynamics of the disease, seroepidemological study are necessary.

Most of studies in Iran are about adults; especially volunteer blood donors, female population, students of a university, or pregnant women who were referred to a medical laboratory, clinic, or hospital.

The purpose of the study was to investigate the age-stratified seroprevalence and epidemiological characteristics of CMV infection in total population of Isfahan state, central Iran.

**METHODOLOGY**

In a descriptive cross-sectional study 594 serum samples were accidentally selected from among 820 frozen samples. These samples were collected by multistage cluster sampling method from whole inhabitants of Isfahan state, Iran in a seroepidemiological survey on hepatitis A in 2008. All participants agreed and assigned written informed consent to partake in the epidemiological studies on their serums. The research was approved by the regional bioethics committee of the Research Department of Isfahan University of Medical Sciences.

Frozen samples were liquefied in room temperature and examined for IgG anti-CMV antibody with a commercial enzyme-linked immunosorbent assay (ELISA) kit (Dia-Pro, Milan, Italy). In accordance to the protocol of the kit absorbance values less than 9 reported negative, 9-11 equivocal, and more than 11 positive. The serums with borderline absorbance was reexamined and accordingly reported as negative or positive. If the test has borderline result again the serum was omitted from the research.

Ultimately, data analysis was performed with the Statistical Package for Social Sciences SPSS for Windows version 15 (SPSS Inc., Chicago IL.). Chi-square and Fisher exact tests were used to examine seroprevalence in different age, sex, education, family member, marriage state, and residency groups in the studied people. A P-value of less than 0.05 was considered significant.

**RESULTS**

Out of 595 serum samples examined, results of 585 cases were positive, 9 were negative and one sample was equivocal. On re-examination of this sample, the result was negative. According to these results, the prevalence of the CMV infection in total inhabitants of Isfahan state, Iran was 98.2%. The distribution of age, and residence area in participants was comparable to that of the total inhabitant of Isfahan state in the time of the survey. The seroprevalence of CMV infection in various age groups has been represented in Table-I.
DISCUSSION

The overall CMV seroprevalence in Isfahan state was 98.2%. The seroprevalence was 94% in Orumie city in Iran and varies from 59.2% to 97.3% in reports of other countries: Turkey (97.3%), Jamaica (95%), Portugal (77%), Spain (62.8%), Ghana (59.2%), and Australia (57%). The high prevalence of CMV in Iran and other developing countries is due to cultural and socioeconomic status like breast feeding, child rearing practices, and child group activities.

Seroprevalence of CMV infection in age groups of 6-9 and 10-19 were 95.3% and 98.3% respectively. These results were similar to reports from Cameroon, Brazil, Turkey, and Orumieh of Iran. But they are higher than rates of Taiwan, Italy, America, and Finland. The high prevalence in these age groups revealed that congenital, cervico-vaginal, breast feeding and horizontal transfer in kindergartens are the major roots of acquiring infection in the community, and sexual contact has no significant role in transmission of CMV infection in the state. Due to prolonged excretion of CMV after primary infection and also high rate of primary infection in infants and small children, to prevent re-infection of pregnant women with new CMV strain, all pregnant women should be advised to take care of them from exposure to infant’s secretions especially urine and saliva.

In another study in Iran the reported CMV prevalence in age groups of less than 1, 1-5, and higher than 5 years old were 73.9%, 73.9%, and 97% respectively. It shows that the role of congenital, perinatal conditions, and breast feeding in transmission of CMV would be more important than children contact in kindergartens.

In current study anti CMV antibody in groups aged 10-19, 20-29 and 30-39 were 98.3%, 97.8%, and 100% respectively. It shows almost all community members after 10 years of age are CMV seropositive. So the chance for finding CMV seronegative donor in organ transplantation or blood transfusion in the community is very low. Therefore after hematopoietic or solid organ transplantation enough searches should be made to diagnose and treat CMV disease appropriately. In addition irradiated blood products should be requested for blood transfusion of premature infants and immunodeficient cases in these areas. Our results were comparable to results from other parts of Iran. Asymptomatic blood donors in Tabriz (82%), Tehran (89.2%), and Kashan (97%) also had high CMV seroprevalence rates. Estimated prevalence in blood donors of India (95%) and France (97.1%) were near to our prevalence.

In our research anti CMV antibody in women aged 10-19, 20-29, and 30-39 in order were 98.3%, 97.8%, and 100%. Similar high rates in child bearing aged and pregnant women were reported from other parts of Iran i.e. Fars, Azerbaijan, Kazeron, Tehran, Kerman, south of Iran, Gonabad, and also Jordan, Saudi Arabia and Turkey. In contrast CMV seroprevalence in pregnant women of developed countries like Ireland (4.4%), Italy (30.7%), and Netherland (41%) is low to moderate. It shows that most women in Isfahan state and may be other parts of Iran are CMV seropositive before pregnancy and so the chance of symptomatic congenital infection is low. On the other hand approximately 1-1.4 percent of these immune mothers could bear asymptomatic CMV infected child following secondary maternal CMV infection. Unfortunately these infections cannot be diagnosed by screening in pregnancy. With an estimated 5 percent of permanent auditory loss and neurologic disturbances in this newborns, it seems that 5 to 7 in 10,000 live birth in the province has CMV related complications. Because of so high CMV related sequelae all newborns of the region should be properly examined and offered to perform repeated auditory exam till 5 years old to diagnose and treat this problem in time.

Table-I: The total number of participant and their CMV seroprevalence in accordance to age groups.

| Age group (Years) | Total No. of participant | CMV seroprevalence (Percent) |
|-------------------|--------------------------|------------------------------|
| 6-9               | 70                       | 95.7                         |
| 10-19             | 73                       | 98.6                         |
| 20-29             | 136                      | 97.8                         |
| 30-39             | 127                      | 100                          |
| 40-49             | 87                       | 96.6                         |
| >49               | 102                      | 100                          |
| Total             | 595                      | 98.2                         |
In this study residence, sex, education, family number, and marital status has no significant relation with CMV seroprevalence in the community. Very high CMV seroprevalence in the studied population could mask the effect of various factors. A similar study in Taiwan showed residence and family member have no effect on CMV prevalence.26 While in Italy36, Netherland37, and France31, the infection was higher in rural areas. In Australia23 and Jordan32 sex has no role in CMV prevalence.13,36 But results of Portugal showed the infection was higher in female gender in ages greater than 10 years. It is associated to frequent relation between mothers and children.20

**Limitations of the study:** We did not evaluate CMV seroprevalence in age of less than 5 years. So we cannot define the exact effect of congenital, perinatal, breast feeding, and horizontal routs in spread of the infection in the community.

**CONCLUSION**

This study has revealed a very high prevalence of CMV infection in Isfahan province which acquired during early childhood. Taking care is necessary to prevent secondary infection of the pregnant women, primary infection of the premature infants, and reactivated infection of the immune deficient or organ recipient individuals appropriately. In addition repeated auditory exam in children till 5 years old to diagnosis and treatment of asymptomatic congenitally infected children has paramount importance.

**ACKNOWLEDGMENTS**

This research has been performed with a grant from Isfahan University of Medical Sciences. The authors are thankful to Mr. Ahmad Reza Pahlekan and Ms. Parisa Shoaei for their valuable assistance in laboratory studies of this project.

**REFERENCES**

1. Demmler- Harrison GJ. Cytomegalovirus. In: Feigin RD, Cherry JD, Demmler- Harrison GJ, Kaplan Sheldan, editors. Textbook of Pediatric Infectious Diseases, Philadelphia, PA: Saunders; 2009:2022-2043.
2. Stagno S. Cytomegalovirus. In: Kliegman Rm, Stanton BF, Schor NF, Geme III J, Behrman RE, editors. Nelson Textbook of Pediatrics, Philadelphia, Elzevier: Saunders; 2011:1115-1117.
3. Hamprech K, Maschmann J, Vochem M, Dietz K, Speer CP, Jahn G. Epidemiology of transmission cytomegalovirus from mother to preterm infants by breast feeding. Lancet. 2001;357:513-518.
4. Zalel Y, Gilboa Y, Berkenshtat M, Yoeli R, Auslander R, Achiron R, Goldberg Y. Secondary cytomegalovirus infection can cause severe fetal sequelae despite maternal preconceptional immunity. Ultrasound Obstet Gynecol. 2008;31(4):417-420.
5. Karen B, Fowler M, Faye P, McCollister P, Arthur J, Dahle L, et al. Progressive and fluctuating sensorineural hearing loss in children with asymptomatic congenital cytomegalovirus infection. J Pediatr. 1997;130(4):624-630.
6. Oskoui MR. Study of CMV infection in 200 blood donors in Tabriz blood transfusion organization center. Tbz Uni Med J. 1993;23:41-46.
7. Aghaeipour M, Tarabadi FA, Shaiegan M, Babaei GH. Detection of serologic prevalence of anti-CMV antibodies in thalassemia major patients and blood donors. Blood. 2003;2:37-41.
8. Moniri R, Mosayebi Z, Mousavi GhA. Seroprevalence of cytomegalovirus, hepatitis B, hepatitis C and human immunodeficiency virus antibodies among volunteer blood donors. Iran J Public Health. 2004;38:42-48.
9. Arapbour M, Kaviayanees K, Jankhah A, Yaghoubi R. Human CMV infection in women of child bearing age throughout Fars Province Iran: a population based study. Int J Iran Red Cres Soc. 2010;10(2):102-106.
10. Rajaii M. Evaluation of immunity against CMV in Azarbayjan female population. Iranian J Clin Infec Dis. 2008;3(3):143-148.
11. Taiebi D, Tabatabaei M, Ralhsaz M, Sharifi E, Shariati M, Sohrabi E. Seroepidemiology of Cmv in student Kazeroon Azad university. Iran J of Epidemiol. 2009;5(3):55-60.
12. Siadati A, Noorbakhsh S, Ghazi F, Kimaz SH, Monavvari MR. Cytomegalovirus infection in primiparous pregnant women and their neonates. Acta Med Iranica J. 2002;3:136-139.
13. Arabzadeh AM, Mosavat SA, Eftekhari N. Seroepidemiology of Human Cytomegalovirus in pregnant women and their neonates in Kerman City during 2005. J Kerman Univ Med Sci. 2007;14(4):279-288.
14. Jahromi AS, Makiani MJ, Farjam MR, Madani A, Amirian M, Eftekhri TE, et al. Cytomegalovirus Immunity in Pregnancy in South of Iran. Am J Infect Dis. 2010;6(1):8-12.
15. Bagheri L, Mokhtarian H, Sarshar N, Ghahramani M. Seroepidemiology of Cytomegalovirus Infection during Pregnancy in Gonabad, Eastern Iran: A Cross-Sectional Study, J Res Health Sci. 2012;12(1):38-44.
16. Ataei B, Javadi AA, Nokhdian Z, Kassaeian N, Shoaei P, Farajzadegan Z, et al. HAV in Isfahan province a population-based study. Trop Gastroenterol. 2008;29(3):160-162.
17. Hamkar R, Azarian B, Saadatmand Z, Nouruzbabaie Z, Esamlu F, Mokhtari T. Seroepidemiologic study of cytomegalovirus in under 45 years old people in orumie. Iranian J Infect Dis Trop Med. 2005;10(3):29-33.
18. Ataman S, Colak D, Günseren F, Senol Y, Colak T, Gültekin M, et al. Investigation of cytomegalovirus seroepidemiology in Antalya with a population-based cross-sectional study and review of related data in Turkey. Mikrobiyol Bul. 2007;41(4):545-555.
19. Prabhakar P, Bailey P, Smikle MF, Ashley D. Seroprevalence of CMV infection in a selected population in Jamaica. West Indian Med J. 2002;51(3):299-302.
20. Lopo S, Vinagre E, Palminha P, Paixao MT, Nogueira P, Freitas MG. Seroprevalence to cytomegalovirus in Portuguese population, 2002-2003. Euro Surveill. 2011;16(25):pii=19896. Available online: http://www.eurosurveillance.org/ ViewArticle. aspx?ArticleId=19896
21. de Ory F, Sanz JC, Castaneda R, Ramirez R, Leon P, Pachon I. Cytomegalovirus seroepidemiology in the community of Madrid. Rev Esp Salud Publica. 2001;75(1):55-62.
22. Adjei AA, Armah HB, Gbagbo F, Boamah I, Adu-Gyamfi C, Asare I. Seroprevalence of HHV-8, CMV, and EBV among the general population in Ghana, West Africa. BMC Infect Dis. 2008;8:111.
23. Seale H, Macintyre CR, Gidding HF, Backhouse JL, Dwyer DE, Gilbert L. National serosurvey of cytomegalovirus in Australia. Clin Vaccine Immunol. 2006;13:1181-1184.
24. Stroffolini T, Ngatchu T, Chiaramonte M, Giammanco A, Maggio M, Sarzana A, et al. Prevalence of cytomegalovirus seropositivity in an urban child population in Cameroon. New Microbiol. 1993;16:83-85.
25. Almeida LN, Azevedo RS, Amaku M, Massad E. Cytomegalovirus seroepidemiology in an urban community of Sao Paulo, Brazil. Rev Saude Publica. 2001;35(2):124-129.
26. Shen CY, Chang WW, Chang SF, Chao MF, Huang ES, Wu CW. Seroepidemiology of cytomegalovirus infection among children between the ages of 4 and 12 years in Taiwan. J Med Virol. 1992;37:72-75.
27. de Mattia D, Stroffolini T, Arista S, Pistoia D, Giammanco A, Maggio M, et al. Prevalence of cytomegalovirus infection in Italy. Epidemiol Infect. 1991;107(2):421-427.
28. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of Cytomegalovirus infection in the United States 1988-1994. Clin Infect Dis. 2006;43(9):1143-1451.
29. Aarnisalo J, Ilonen J, Vainionpaa R, Volanen I, Kaitosaari T, Simell O. Development of antibodies against cytomegalovirus, varicella-zoster virus and herpes simplex virus in Finland during the first eight years of life: a prospective study. Scand J Infect Dis. 2003;35:750-753.
30. Kothari A, Ramachandran VG, Gupta P, Singh B, Talwar V. Seroprevalence of cytomegalovirus among voluntary blood donors in Delhi, India. J Health Popul Nutr. 2002;20:348-351.
31. Gargouri J, Elleuch H, Karray H, Pekik H, Hammami A. Prevalence of anti-CMV antibodies in blood donors in the Sfax region (value in blood transfusion). Tunis Med. 2000;78(8-9):512-517.
32. Abuharfeil N, Meqdam MM. Seroepidemiologic study of herpes simplex virus type 2 and cytomegalovirus among young adults in northern Jordan. New Microbiol. 2000;23(3):235-239.
33. Ghazi HO, Telmesani AM, Mahomed MF. TORCH agents in pregnant Saudi women. Med Princ Pract. 2002;11(4):180-182.
34. Uyar Y, Balık A, Akalı A, Cabar C. Prevalence of rubella and cytomegalovirus antibodies among pregnant women in northern Turkey. New Microbiol. 2008;31(4):451-455.
35. Knowles SJ, Grundy K, Cahill I, Cafferkey MT, Geary M. Low cytomegalovirus sero-prevalence in Irish pregnant women. Ir Med J. 2005;98(7):210-212.
36. Stagno S, Pass RF, Cloud G. Primary cytomegalovirus infection in pregnancy. Incidence transmission to fetus and clinical outcome. J Am Med Assoc. 1986;256:1904-1908.
37. Gaytant MA, Galama JM, Semmekrot BA, Melchers WJ, Sporken JM, Oosterbaan HP, et al. The incidence of congenital CMV infection in the Netherlands. J Med Virol. 2005;76(1):71-75.
38. Fowler KB, Stagno S, Pass RF. Maternal Immunity and Prevention of Congenital Cytomegalovirus Infection. JAMA. 2003;289(8):1008-1011.
39. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253-276.
40. Ahlfors K, Ivarsson SA, Harris S. Report on a Long-term Study of Maternal and Congenital Cytomegalovirus Infection in Sweden. Scand J Infect Dis. 1999;31(5):443-457.
41. Gratacap-Cavallier B, Bosson J, Morand P, Duterre N, Chanzy B, Seigneurin J, et al. Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors. Eur J Epidemiol. 1998;14(2):147-152.

Authors Contributions:

SNA contributed in study design and prepared the first draft of the manuscript. BA, ZN, MY, AS conceived the study design and contribute in data gathering. AB was involved in data analysis and interpretation of the results. All authors have read and approved the content of the manuscript.